Top Story

Apabetalone fails to benefit MACE, but ‘cautious optimism’ remains

November 18, 2019
In the Journals

Mortality risk heightened with diabetic ketoacidosis plus hyperosmolar hyperglycemic state

November 18, 2019
Mortality risk is higher for adults admitted to the hospital with both diabetic ketoacidosis and hyperosmolar hyperglycemic state, than for those presenting with either…
In the Journals

Greater renal benefits seen with bariatric surgery vs. medications in pediatric type 2 diabetes, obesity

November 18, 2019
Adolescents with type 2 diabetes and obesity may be at lower risk for developing diabetic kidney disease if they receive bariatric surgery compared with medical…
Meeting NewsPerspective

DAPA-HF: Dapagliflozin’s HF benefits consistent regardless of age, symptom severity

November 17, 2019
PHILADELPHIA — Treatment with the SGLT2 inhibitor dapagliflozin reduced risk for CV death and worsening HF across a broad spectrum of age, independent of…
Meeting NewsPerspective

Dapagliflozin confers consistent benefit in HF without diabetes: DAPA-HF

November 16, 2019
PHILADELPHIA — New analyses of the DAPA-HF trial suggest that the benefits of the SGLT2 inhibitor dapagliflozin extend beyond its effects as a type 2 diabetes…
More Headlines »

Ace the Case: A 19-Year-Old Man With Uncontrolled Type 1 Diabetes Mellitus

There is no commercial support for this activity.

This educational activity will utilize a case study to discuss the management of a 19-year-old man with uncontrolled…
More »
Meeting News

VIDEO: ‘Hacked,’ DIY devices ‘work better,’ present teaching opportunities

August 12, 2019
More »
Resource Centers



Point-of-Care201: GLP-1 Receptor Agonists in Type 2 Diabetes: Mechanistic Insights and Evolving Treatment Options

This activity is supported by an independent educational grant from Novo Nordisk Inc.

Individualizing and achieving glycemic targets are critical to optimizing type 2 diabetes mellitus (T2DM) outcomes…
More »
Current Issues
View the Current Issue